Latest estimates point to slowly rising health spending growth, according to OECD Health Statistics 2016. While health spending growth remains somewhat below pre-crisis rates, it has tended to follow economic growth more closely since 2013. This is in contrast to the years leading up to the economic crisis, when growth in health spending strongly outpaced that in the rest of the economy.
The OECD Health Division is releasing a new series to highlight its work on health policies and data. A new graph will be available each month.
The OECD carries out work on health data and indicators to improve international comparisons and economic analyses of health systems.
Health workers are crucial for ensuring access to high quality care for the whole population. The OECD advises countries on how to meet future demand for health professionals and how to manage the supply of health workers, by reviewing policies related to education and training, continuous professional development, geographic distribution and immigration.
OECD Health Statistics 2016 is the most comprehensive source of comparable statistics on health and health systems across OECD countries.
The objective of the HCQI Project is to develop a set of indicators based on comparable data and which can be used to raise questions for further investigation on quality differences across countries.
The OECD Development Assistance Committee (DAC) collects aid flows at activity level based on a standard methodology and agreed definitions. Aid to Health is covered by two main sectors; 1.Aid to Health - General and Basic Health, and, 2. Population Policies/Programmes and Reproductive Health - includes HIV/AIDS.
English, Excel, 4,115kb
Download this selection of key indicators from OECD Health Statistics 2016, in Excel. 2016 version, updated 30 June 2016.
Download data on health expenditure, health care resources, health care activities, mortality, and risk factors. Latest data in Excel format from the database OECD Health Statistics 2014, November 2014 edition.
Statistics on biotechnology firms, biotechnology R&D (including public sector expenditures), biotech applications and patents.